 Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Descriptor ID |
D018284
|
| MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
| Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 3 | 0 | 3 | | 2014 | 1 | 1 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2020 | 2 | 0 | 2 | | 2021 | 1 | 0 | 1 | | 2022 | 2 | 1 | 3 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Bapat J, Yamamoto TM, Woodruff ER, Qamar L, Mikeska RG, Aird KM, Watson ZL, Brubaker LW, Bitler BG. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR. Cancer Gene Ther. 2024 02; 31(2):300-310.
-
Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines? Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 09; 20(9):972-980.
-
Sanders BE, Yamamoto TM, McMellen A, Woodruff ER, Berning A, Post MD, Bitler BG. Targeting DUSP Activity as a Treatment for High-Grade Serous Ovarian Carcinoma. Mol Cancer Ther. 2022 08 02; 21(8):1285-1295.
-
Renner CM, Visetsouk MR, Kreeger PK, Masters KS. Multispectral Staining and Analysis of Extracellular Matrix. Methods Mol Biol. 2022; 2424:105-119.
-
Dou Z, Qiu C, Zhang X, Yao S, Zhao C, Wang Z, Chu R, Chen J, Chen Z, Li R, Wang K, Liu P, Liu C, Song K, Kong B. HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer. Int J Biol Sci. 2022; 18(3):1188-1210.
-
Renner C, Gomez C, Visetsouk MR, Taha I, Khan A, McGregor SM, Weisman P, Naba A, Masters KS, Kreeger PK. Multi-modal Profiling of the Extracellular Matrix of Human Fallopian Tubes and Serous Tubal Intraepithelial Carcinomas. J Histochem Cytochem. 2022 02; 70(2):151-168.
-
Wu YHA, Samuels JM, Harnke B, Negrini D, Al-Musawi MH, Meguid C, Ahrendt S, Schulick RD, Del Chiaro M, Oba A. Multifocal/diffuse pancreatic serous cystic neoplasms: Systematic review with a new case. Pancreatology. 2020 Jul; 20(5):902-909.
-
Sawyer BT, Qamar L, Yamamoto TM, McMellen A, Watson ZL, Richer JK, Behbakht K, Schlaepfer IR, Bitler BG. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression. Mol Cancer Res. 2020 07; 18(7):1088-1098.
-
Galey MM, Young AN, Petukhova VZ, Wang M, Wang J, Salvi A, Russo A, Burdette JE, Sanchez LM. Detection of Ovarian Cancer Using Samples Sourced from the Vaginal Microenvironment. J Proteome Res. 2020 01 03; 19(1):503-510.
-
Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|